Alessandra Esposito

Dr. Alessandra Esposito

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2024 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
JHJacobi B. Hines
Jacobi B. Hines
RCRobert B. Cameron
Robert B. Cameron
AEAlessandra Esposito
Alessandra Esposito
LKLeeseul Kim
Leeseul Kim
LPLuca Porcu
Luca Porcu
VTValter Torri
Valter Torri
Controversy remains as to whether pathologic complete response (pCR) and major pathologic response (MPR) represent surrogate endpoints for event free survival (EFS) and overall survival (OS) in neoadjuvant trials for resectable non-small cell lung cancer (NSCLC). A search of PubMed and archives of international conference abstracts was performed from June 2017 through October 31, 2023. Studies incorporating a neoadjuvant arm with immune checkpoint blockade alone or in combination with chemotherapy were included. Those not providing information regarding pCR, MPR, EFS or OS were excluded. For trial level surrogacy, log Odds Ratios (OR)s for pCR and MPR and log Hazard Ratios (HR) for EFS and OS were analyzed using a linear regression model weighted by sample size. The regression coefficient and R2 with 95% CI were calculated by bootstrapping approach. Seven randomized clinical trials were identified for a total of 2385 patients. At the patient level, the R2 of pCR and MPR with 2-year EFS were 0.82 (0.66-0.94) and 0.81 (0.63-0.93), respectively. OR of 2-year EFS rates by response status were 0.12 (0.07-0.19) and 0.11 (0.05-0.22), respectively. For 2-year OS, the R2 of pCR and MPR were 0.55 (0.09-0.98) and 0.52 (0.10-0.96), respectively. At trial level, R2 for association of OR for response and HR for EFS was 0.58 (0.00-0.97) and 0.61 (0.00-0.97), respectively. Our analyses demonstrate a robust correlation between pCR and MPR with 2-year EFS but not OS. Trial-level surrogacy was moderate but imprecise. More mature follow-up and data to assess the impact of study crossover are needed.

16 October 2012 in Diabetologia
Verified
Journal Article
Closed access
PDF file
Maria  Luisa BalestrieriMaria Luisa Balestrieri
Maria Luisa Balestrieri
LSL. Servillo
L. Servillo
AEAlessandra Esposito
Alessandra Esposito
Nunzia D'OnofrioNunzia D'Onofrio
Nunzia D'Onofrio
AGA. Giovane
A. Giovane
RMR. Marfella
R. Marfella

1 June 2017 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
HWHelen Willcockson
Helen Willcockson
JTJ.D. Temple
J.D. Temple
LTL. Tagliafierro
L. Tagliafierro
HWH. Willcockson
H. Willcockson
AEAlessandra Esposito
Alessandra Esposito
ASA. Spagnoli
A. Spagnoli

8 May 2019 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
TLTieshi Li
Tieshi Li
SCSusan Chubinskaya
Susan Chubinskaya
AEAlessandra Esposito
Alessandra Esposito
XJXin Jin
Xin Jin
LTLidia Tagliafierro
Lidia Tagliafierro
ASAnna Spagnoli
Anna Spagnoli
Mechanisms that govern the shift from joint homeostasis to osteoarthritis (OA) remain unknown. Here, we identify a pathway used for joint development and homeostasis, and its role in OA. Using a combination of transgenic, pharmacological, and surgical conditions in mouse and human tissues, we found that TGF-β signaling promotes joint homeostasis through regulation of the IL-36 family. We identified IL-36 receptor antagonist (IL-36 in mice and IL-36RN in humans) as a potential disease-modifying OA drug. Specifically, OA development was associated with IL-36α up-regulation and IL-36Ra down-regulation in mice with tissue-specific postnatally induced ablation of Tgfbr2, mice treated with a TGF-β signaling inhibitor, mice with posttraumatic OA, and aging mice with naturally occurring OA. In human cartilage, OA severity was associated with decreased TGFBR2 and IL-36RN, whereas IL-36α increased. Functionally, intra-articular treatment with IL-36Ra attenuated OA development in mice, and IL-36RN reduced MMP13 in human OA chondrocytes. These findings highlight the relevance of TGFBR2–IL-36 interplay in joint homeostasis and IL-36RN as a potential therapeutic agent for OA.

26 October 2023 in European Journal of Cancer
Verified
Journal Article
Closed access
ANAntonio Nuccio
Antonio Nuccio
GVGiuseppe Viscardi
Giuseppe Viscardi
FSFabio Salomone
Fabio Salomone
ASAlberto Servetto
Alberto Servetto
FVFrancesco Maria Venanzi
Francesco Maria Venanzi
RFRoberto Ferrara
Roberto Ferrara

3 July 2020 in Bone
Verified
Journal Article
Closed access
AEAlessandra Esposito
Alessandra Esposito
LWLai Wang
Lai Wang
TLTieshi Li
Tieshi Li
MMMariana Miranda
Mariana Miranda
ASAnna Spagnoli
Anna Spagnoli